Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Active Ingredients:
Dosage Form: New Zealand Sponsor: Manufacturers:
|
Influvac Tetra Influenza virus A/California/7/2009 (H1N1) – like strain 15mcg Influenza virus A/Texas/50/2012 (H3N2) – like strain 15mcg Influenza virus B/Brisbane/60/2008 – like strain 15mcg Influenza virus B/Massachusetts/2/2012 – like strain 15mcg Suspension for injection Mylan New Zealand Limited Abbott Biologicals BV, Olst, Netherlands Abbott Biologicals BV, Weesp, Netherlands
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturers:
|
Somatuline Autogel Lanreotide acetate 77.9mg equivalent to lanreotide 60mg Solution for injection Pharmacy Retailing (NZ) Limited trading as Healthcare Logistics Ipsen Pharma Biotech, Signes, France Ipsen Pharma Biotech, Marseille, France Sterigenics Italy S.P.A, Bologne, Italy
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturers:
|
Somatuline Autogel Lanreotide acetate 113.6mg equivalent to lanreotide 90mg Solution for injection Pharmacy Retailing (NZ) Limited trading as Healthcare Logistics Ipsen Pharma Biotech, Signes, France Ipsen Pharma Biotech, Marseille, France Sterigenics Italy S.P.A, Bologne, Italy
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturers:
|
Somatuline Autogel Lanreotide acetate 149.4mg equivalent to lanreotide 120mg Solution for injection Pharmacy Retailing (NZ) Limited trading as Healthcare Logistics Ipsen Pharma Biotech, Signes, France Ipsen Pharma Biotech, Marseille, France Sterigenics Italy S.P.A, Bologne, Italy
|
Dated this 12th day of October 2017.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).